AIMS: To investigate whether coadministration of the antimalarials artesunate and artemisinin alters the clearance of either drug. METHODS:Ten healthy Vietnamese males (Group AS) were randomized to receive a single dose of 100 mg oral artesunate (pro-drug of dihydroartemisinin) on day -5 and then once daily for 5 consecutive days (days 1-5). Oral artemisinin (500 mg) was coadministered on days 1 and 5. Another 10 subjects (Group AM) were given 500 mg oral artemisinin on day -5 and then further doses on days 1-5. Artesunate 100 mg was given on days 1 and 5. Artemisinin and dihydroartemisinin plasma concentrations on days -5, 1 and 5 were quantified by h.p.l.c. with on-line postcolumn derivatization and u.v. detection. RESULTS: In Group AS, dihydroartemisinin oral clearance values (mean (95% CI)) were similar on day 1 (32 (22, 47)) l h(-1) and day 5 (38 (28, 51)) l h(-1) of daily artesunate administration but these mean values were approximately three fold higher compared with day -5 after a single dose (95 (56, 159)). In this group, artemisinin oral clearance increased from 196 (165, 232) l h(-1) on day 1-315 (241, 410) l h(-1) on day 5. In Group AM, dihydroartemisinin oral clearance on day 1 was 39 (34, 46) l h(-1) and increased 1.6 fold to 64 (48, 85) l h(-1) on day 5. In this group, artemisinin oral clearance increased sequentially (1.5 and 4.7 fold, respectively) from 207 (151, 285) l h(-1) on day -5-308 (257, 368) l h(-1) on day 1 and to 981 (678, 1420) l h(-1) on day 5. The increase in artemisinin oral clearance between days -5 and 1 (in the absence of artesunate) was similar to that between days 1 and 5 in Group AS subjects who took daily artesunate. Dihydroartemisinin was not a significant metabolite of artemisinin. CONCLUSIONS:Artesunate (dihydroartemisinin) did not alter the elimination of artemisinin. However, dihydroartemisinin elimination was inhibited by artemisinin. Artemisinin induced its own elimination even 5 days after a single oral dose. There was no evidence for the formation of dihydroartemisinin from artemisinin.
RCT Entities:
AIMS: To investigate whether coadministration of the antimalarials artesunate and artemisinin alters the clearance of either drug. METHODS: Ten healthy Vietnamese males (Group AS) were randomized to receive a single dose of 100 mg oral artesunate (pro-drug of dihydroartemisinin) on day -5 and then once daily for 5 consecutive days (days 1-5). Oral artemisinin (500 mg) was coadministered on days 1 and 5. Another 10 subjects (Group AM) were given 500 mg oral artemisinin on day -5 and then further doses on days 1-5. Artesunate 100 mg was given on days 1 and 5. Artemisinin and dihydroartemisinin plasma concentrations on days -5, 1 and 5 were quantified by h.p.l.c. with on-line postcolumn derivatization and u.v. detection. RESULTS: In Group AS, dihydroartemisinin oral clearance values (mean (95% CI)) were similar on day 1 (32 (22, 47)) l h(-1) and day 5 (38 (28, 51)) l h(-1) of daily artesunate administration but these mean values were approximately three fold higher compared with day -5 after a single dose (95 (56, 159)). In this group, artemisinin oral clearance increased from 196 (165, 232) l h(-1) on day 1-315 (241, 410) l h(-1) on day 5. In Group AM, dihydroartemisinin oral clearance on day 1 was 39 (34, 46) l h(-1) and increased 1.6 fold to 64 (48, 85) l h(-1) on day 5. In this group, artemisinin oral clearance increased sequentially (1.5 and 4.7 fold, respectively) from 207 (151, 285) l h(-1) on day -5-308 (257, 368) l h(-1) on day 1 and to 981 (678, 1420) l h(-1) on day 5. The increase in artemisinin oral clearance between days -5 and 1 (in the absence of artesunate) was similar to that between days 1 and 5 in Group AS subjects who took daily artesunate. Dihydroartemisinin was not a significant metabolite of artemisinin. CONCLUSIONS:Artesunate (dihydroartemisinin) did not alter the elimination of artemisinin. However, dihydroartemisinin elimination was inhibited by artemisinin. Artemisinin induced its own elimination even 5 days after a single oral dose. There was no evidence for the formation of dihydroartemisinin from artemisinin.
Authors: N X Khanh; P J de Vries; L D Ha; C J van Boxtel; R Koopmans; P A Kager Journal: Antimicrob Agents Chemother Date: 1999-03 Impact factor: 5.191
Authors: U S Svensson; M Ashton; N H Trinh; L Bertilsson; X H Dinh; V H Nguyen; T N Nguyen; D S Nguyen; J Lykkesfeldt; D C Le Journal: Clin Pharmacol Ther Date: 1998-08 Impact factor: 6.875
Authors: M B van Hensbroek; E Onyiorah; S Jaffar; G Schneider; A Palmer; J Frenkel; G Enwere; S Forck; A Nusmeijer; S Bennett; B Greenwood; D Kwiatkowski Journal: N Engl J Med Date: 1996-07-11 Impact factor: 91.245
Authors: F Nosten; C Luxemburger; F O ter Kuile; C Woodrow; J P Eh; T Chongsuphajaisiddhi; N J White Journal: J Infect Dis Date: 1994-10 Impact factor: 5.226
Authors: Harin A Karunajeewa; Kenneth F Ilett; Kitiya Dufall; Adedayo Kemiki; Moses Bockarie; Michael P Alpers; P Hugh Barrett; Paolo Vicini; Timothy M E Davis Journal: Antimicrob Agents Chemother Date: 2004-08 Impact factor: 5.191
Authors: Johannes Nagelschmitz; Barbara Voith; Georg Wensing; Axel Roemer; Burkhard Fugmann; Richard K Haynes; Barbara M Kotecka; Karl H Rieckmann; Michael D Edstein Journal: Antimicrob Agents Chemother Date: 2008-06-16 Impact factor: 5.191
Authors: O Burk; R Piedade; L Ghebreghiorghis; J T Fait; A K Nussler; J P Gil; B Windshügel; M Schwab Journal: Br J Pharmacol Date: 2012-10 Impact factor: 8.739
Authors: Miriam K Laufer; Phillip C Thesing; Fraction K Dzinjalamala; Osward M Nyirenda; Rhoda Masonga; Matthew B Laurens; Abbie Stokes-Riner; Terrie E Taylor; Christopher V Plowe Journal: PLoS One Date: 2012-08-17 Impact factor: 3.240